Results 251 to 260 of about 3,585,369 (296)

Tumor and germline testing with next generation sequencing in epithelial ovarian cancer: a prospective paired comparison using an 18‐gene panel

Molecular Oncology, EarlyView.
Genetic testing in epithelial ovarian cancer includes both germline and tumor‐testing. This approach often duplicates resources. The current prospective study assessed the feasibility of tumor‐first multigene testing by comparing tumor tissue with germline testing of peripheral blood using an 18‐gene NGS panel in 106 patients.
Elisabeth Spenard, Cristina Mitric, Melanie Care, Tracy L. Stockley, Raymond H. Kim, Jeanna McCuaig, Blaise Clarke, Laura Ranich, Clare Sheen, Sarah E. Ferguson, Liat Hogen, Taymaa May, Marcus Q. Bernardini   +12 more
wiley   +1 more source

Artificial Intelligence in Cancer Oncology Through Comprehensive Bibliometric Mapping of Global Trends Impact and Conceptual Structures. [PDF]

J Healthc Leadersh
Caraka RE, Supardi K, Gondhowiardjo SA, Isnaniawardhani V, Gio PU, Chen RC, Pardamean B.   +6 more
europepmc   +1 more source

The neural crest‐associated gene ERRFI1 is involved in melanoma progression and resistance toward targeted therapy

Molecular Oncology, EarlyView.
ERRFI1, a neural crest (NC)‐associated gene, was upregulated in melanoma and negatively correlated with the expression of melanocytic differentiation markers and the susceptibility of melanoma cells toward BRAF inhibitors (BRAFi). Knocking down ERRFI1 significantly increased the sensitivity of melanoma cells to BRAFi.
Nina Wang, Qian Sun, Daniel Novak, Lei Zhu, Juliane Poelchen, Tamara Steinfass, Yiman Wang, Viktor Umansky, Jochen Utikal   +8 more
wiley   +1 more source

A highly accurate risk factor-based XGBoost multiethnic model for identifying patients with skin cancer. [PDF]

Nat Commun
D'Antonio M, G Gonzalez Rivera W, Greenes RA, Gymrek M, Frazer KA.   +4 more
europepmc   +1 more source

Plasma extrachromosomal circular DNA as a biomarker in EGFR‐targeted therapy of non‐small cell lung cancer

Molecular Oncology, EarlyView.
Detection of extrachromosomal circular DNA (eccDNA) in plasma samples from EGFR‐mutated non‐small cell lung cancer patients. Plasma was collected before and during treatment with the EGFR‐tyrosine kinase inhibitor osimertinib. Plasma eccDNA was detected in all cancer samples, and the presence of the EGFR gene on eccDNA serves as a potential biomarker ...
Simone Stensgaard, Sarmad Mehmood, Eva Boysen Fynboe Ebert, Peter Meldgaard, Anindya Dutta, Boe S. Sorensen   +5 more
wiley   +1 more source

Associations of Commonly Used Concomitant Medications With Survival and Adverse Event Outcomes in Breast Cancer. [PDF]

Cancer Med
Modi ND, Abuhelwa AY, Kuderer NM, Li LX, Lyman GH, Koczwara B, Kichenadasse G, Selth LA, Rickard C, Haseloff M, Vitry A, Woodman R, Logan JM, Ng HS, Wiese MD, McKinnon RA, Rowland A, Sorich MJ, Hopkins AM.   +18 more
europepmc   +1 more source

Prevenir para não ter: avaliando o conhecimento dos homens sobre prevenção do câncer de próstata

, 2017
Pâmela Scarlatt Durães Oliveira, Rodrigo Marques Batista da Rocha, Vanessa Maia da Silva Nunes Aguiar, Henrique Andrade Barbosa, Jaqueline D`Paula Ribeiro Vieira Torres   +4 more
openalex   +2 more sources

Glycosylated LGALS3BP is highly secreted by bladder cancer cells and represents a novel urinary disease biomarker

Molecular Oncology, EarlyView.
Urinary LGALS3BP is elevated in bladder cancer patients compared to healthy controls as detected by the 1959 antibody–based ELISA. The antibody shows enhanced reactivity to the high‐mannose glycosylated variant secreted by cancer cells treated with kifunensine (KIF).
Asia Pece, Giulio Lovato, Ilaria Cela, Arianna Mercatelli, Benedetta Ferro, Jussi Nikkola, Sara Pagotto, Tommaso Grottola, Vincenzo De Laurenzi, Rossella Cicchetti, Antonio Marchetti, Luigi Schips, Rossano Lattanzio, Stefano Iacobelli, Emily Capone, Peter Black, Mads Daugaard, Michele Marchioni, Gianluca Sala   +18 more
wiley   +1 more source

Multiple polygenic score approach in colorectal cancer risk prediction. [PDF]

Sci Rep
Jiang SJ, Thomas M, Rosenthal EA, Phipps AI, Sakoda LC, van Duijnhoven FJB, Pellatt AJ, Avery CL, Berndt SI, Bishop DT, Castellví-Bel S, Chan AT, Grant RC, Gignoux C, Gsur A, Gunter MJ, Haiman CA, Hoffmeister M, Jarvik GP, Jenkins MA, Keku TO, Küry S, Lee JK, Marchand LL, Moreno V, Newcomb PA, Newton CC, Ogino S, Palmer JR, Pearlman R, Qu C, Schoen RE, Um CY, Van Guelpen B, Visvanathan K, Vymetalkova V, White E, Woods MO, Platz EA, Brenner H, Corley DA, Vogelaar IL, Hsu L, Peters U.   +43 more
europepmc   +1 more source

Survivin and Aurora Kinase A control cell fate decisions during mitosis

Molecular Oncology, EarlyView.
Aurora A interacts with survivin during mitosis and regulates its centromeric role. Loss of Aurora A activity mislocalises survivin, the CPC and BubR1, leading to disruption of the spindle checkpoint and triggering premature mitotic exit, which we refer to as ‘mitotic slippage’.
Hana Abdelkabir, Shalitha Wickrama Arachchige, Sally P. Wheatley   +2 more
wiley   +1 more source